KPL vs SYMBIOTEC: Stock Comparison
SYMBIOTEC PHARMALAB is the larger company by market capitalisation. KWALITY PHARMACEUTICALS L shows a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
KPL leads 4; SYMBIOTEC leads 0 of 7
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | KPL | SYMBIOTEC |
|---|---|---|
| Live Price | ₹3,644.8 | ₹1,513.6 |
| Day Change | -1.15% | 19.04% |
| Volume | 20,631 | 75.4 L |
| 52-Week High | ₹3,949 | ₹1,309.9 |
| 52-Week Low | ₹1,561 | ₹934.2 |
| Distance from 52W High | -7.7% | 15.55% |
Valuation
| Metric | KPL | SYMBIOTEC |
|---|---|---|
| Market Cap | ₹3,762 Cr | ₹9,799 Cr |
| P/E Ratio | 46.42x | — |
| P/B Ratio | 11.35x | — |
| EPS | ₹24.7 | ₹2.24 |
| Book Value | ₹317.96 | — |
| Dividend Yield | 0% | 0% |
Growth
| Metric | KPL | SYMBIOTEC |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 3.33% | 0% |
| Qtr Profit Growth | 1.23% | 0% |
Profitability & Leverage
| Metric | KPL | SYMBIOTEC |
|---|---|---|
| ROE | 20.41% | — |
| ROCE | 17.47% | — |
| Net Margin | 13.39% | 0% |
| Operating Margin | 19.97% | — |
| Debt to Equity | 0.4x | — |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | KPL | SYMBIOTEC |
|---|---|---|
| Promoter Holding | 54.86%▼ 0.01 pp | 33.28% |
| FII Holding | 3.13%▲ 0.34 pp | 3.79%▼ 17.29 pp |
| DII Holding | 0.56%▲ 0.2 pp | 33.17%▲ 5.65 pp |
| Public Holding | 41.44%▼ 0.54 pp | 29.76%▲ 11.64 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KWALITY PHARMACEUTICALS L and SYMBIOTEC PHARMALAB.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.